摘要
目的探究注射用二巯丙磺钠联合还原型谷胱甘肽治疗汞超标的临床疗效。方法选取2019年9月-2021年12月本院收治的慢性汞超标患者100例,随机数表法分为观察组(n=50)和对照组(n=50)。对照组患者接受二巯丙磺钠注射治疗,观察组患者接受二巯丙磺钠联合还原型谷胱甘肽注射治疗,比较两组的临床疗效及疗程,治疗前后晨尿尿汞变化、血浆miRNAs表达量变化和不良反应发生情况。结果观察组治疗总有效率为85.71%,高于对照组的63.27%(χ2=4.332,P=0.037)。治疗第1、2、3个疗程后,观察组晨尿尿汞水平低于对照组(t=3.082、2.376、4.631,P=0.003、0.020、<0.01)。治疗第3个疗程后,观察组miR-92a-3p、miR-486-5p相对表达量低于对照组(t=2.573、2.128,P=0.012、0.036)。治疗期间,两组患者不良反应总发生率比较差异无统计学意义(χ2=0.298,P=0.585)。结论注射用二巯丙磺钠联合还原型谷胱甘肽治疗汞超标具有良好临床疗效,可显著降低患者晨尿尿汞水平、血浆miR-92a-3p、miR-486-5p表达量,且不会增加不良反应,安全有效。
Objective To investigate the clinical effect of unithiol injection combined with reduced glutathione in the treatment of elevated mercury.Methods A total of 100 patients with elevated mercury admitted to the hospital from September 2019 to December 2021 were selected,and divided into observation group(n=50)and control group(n=50)by random number table method.Patients in the control group were treated with unithiol injection,while those in the observation group were treated with unithiol injection combined with reduced glutathione injection.The clinical effect,treatment course,changes in mercury content in morning urine and expression levels of plasma miRNAs,and adverse reactions were compared between the two groups.Results The total treatment response rate in the observation group was higher than that in the control group(85.71%vs.63.27%,χ2=4.332,P=0.037).After the end of the 1st,2nd and 3rd courses of treatment,the urinarymercury level in observation group was lower than that in the control group(t=3.082,2.376,4.631,P=0.003,0.020、<0.01).After the end of the 3rd course of treatment,the relative expression levels of miR-92a-3p and miR-486-5p were lower in the observation group than in the control group(t=2.573,2.128,P=0.012,0.036).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(χ2=0.298,P=0.585).Conclusion Unithiol injection combined with reduced glutathione is effective in the treatment of elevated mercury,which can significantly lower mercury level in morning urine of the patients,and reduce the expression levels of plasma miR-92a-3p and miR-486-5p,without increasing adverse reactions.
作者
王楠
刘胜萍
WANG Nan;LIU Sheng-ping(Department of Occupational disease,Hefei Third People's Hospital,Anhui 230022,China)
出处
《工业卫生与职业病》
CAS
2023年第2期126-129,共4页
Industrial Health and Occupational Diseases
